PHILADELPHIA, March 10, 2011 /PRNewswire/ -- On the occasion of World Kidney Day, Kibow Biotech, Inc. is pleased to announce its renewed commitment, hope and support for the worldwide maintenance of healthy kidney function among all those people with kidney problems.
In addition, Kibow Biotech, Inc. would also like to announce that it has received Institutional Review Board (IRB) approvals for conducting human clinical trials with its patented, proprietary and probiotic dietary supplement product – Kibow® Biotics. These human clinical trials will soon be initiated on dialysis patients at Thomas Jefferson University in Philadelphia, PA and the State University of New York (Downstate Medical Center & King's County Hospital, in Brooklyn, NY). Further IRB approval at The Mayo Clinic in Rochester, MN is pending for Chronic Kidney Disease (CKD) III & IV patients.
The Company's novel probiotic dietary supplement product, Kibow® Biotics, utilizes a patented and proprietary bowel-based uremic toxin reduction technology for use in clinical applications towards maintaining a healthy kidney function. Kibow® Biotics has three probiotic microbial strains that are Generally Recognized As Safe (GRAS) by the U.S. FDA. This status essentially means that Kibow® Biotics is generally known, among skilled scientific and medical experts, as having been adequately shown to be safe under the conditions of its intended use.
Dr. Ranganathan states, "By developing an affordable, readily available and easy-to-administer dietary supplement, Kibow offers hope to all those who suffer from kidney problems in the USA and other countries, while in accordance with their respective governmental regulatory/registration authorities."
About Kibow Biotech:
Kibow Biotech, Inc. is a 13-year-old R&D biotechnology company, having its operations in Newtown Square, PA, USA. The company's mission is ded
|SOURCE Kibow Biotech, Inc.|
Copyright©2010 PR Newswire.
All rights reserved